Role of abciximab in the treatment of coronary artery disease

Expert Opinion on Biological Therapy

Volumn 6, Issue 9, 2006, Pages 935-942

  Gabriel, H Mesquita ^a   Oliveira, Eduardo Infante ^b  

^a HOSPITAL DE SANTA MARIA   (Portugal)

^b NONE

Author keywords

Abciximab; Atherosclerosis; Coronary artery disease; Monoclonal antibody; Platelet antiaggregant

Indexed keywords

ABCIXIMAB; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR; FIBRINOLYTIC AGENT; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN; RETEPLASE; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG COMBINATION; DRUG CONTRAINDICATION; DRUG EFFECT; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; METABOLISM; RANDOMIZED CONTROLLED TRIAL; REVIEW; THROMBOCYTE AGGREGATION; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; ANTIBODIES, MONOCLONAL; CORONARY ARTERIOSCLEROSIS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT PROTEINS; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 33749068520     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.6.9.935     Document Type: Review

References (64)

1. ANTITHROMBOTIC TRIALISTS' COLLABORATION: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br. Med. J. (2002) 324(7329):71-86. (Pubitemid 34073138)
2. NO AUTHORS LISTED: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet (1996) 348(9038):1329-1339. (Pubitemid 26383772)
3. HANKEY GJ, SUDLOW CL, DUNBABIN DW: Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. Cochrane Database Syst. Rev. (2000) (2):CD001246.
4. YUSUF S, ZHAO F, MEHTA SR et al.: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. (2001) 345(7):494-502. (Pubitemid 32758501)
5. BHATT DL, BERTRAND ME, BERGER PB et al.: Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J. Am. Coll. Cardiol. (2002) 39(1):9-14. (Pubitemid 34059855)
6. SILBER S, ALBERTSSON P, AVILES FF et al.: Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur. Heart J. (2005) 26(8):804-847.
7. SMITH SC JR, FELDMAN TE, HIRSHFELD JW JR et al.: ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J. Am. Coll. Cardiol. (2006) 47(1):e1-121.
8. DE SCHRYVER EL, ALGRA A, VAN GIJN J: Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. Cochrane Database Syst. Rev. (2006) (2):CD001820.
9. LITTLE SH, MASSEL DR: Antiplatelet and anticoagulation for patients with prosthetic heart valves. Cochrane Database Syst. Rev. (2003) (4):CD003464.
10. SALEM DN, STEIN PD, AL-AHMAD A et al.: Antithrombotic therapy in valvular heart disease-native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 126(3 Suppl.):457S-482S. (Pubitemid 39297961)
11. CHAPMAN TM, GOA KL: Cilostazol: a review of its use in intermittent claudication. Am. J. Cardiovasc. Drugs (2003) 3(2):117-138. (Pubitemid 36665531)
12. FULLARD JF: The role of the platelet glycoprotein IIb/IIIa in thrombosis and haemostasis. Curr. Pharm. Des. (2004) 10(14):1567-1576. (Pubitemid 38559768)
13. COLLER BS, TOPOL EJ: Glycoprotein IIb/IIIa antagonists: development of abciximab and pharmacology of selected agents. In: Contemporary Cardiology: Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease. Lincoff AM (Ed.), Humana Press, Inc., Totowa, NJ, USA (1999):67-89.
14. CHEW DP, BHATT DL, SAPP S, TOPOL EJ: Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of Phase III multicenter randomized trials. Circulation (2001) 103(2):201-206. (Pubitemid 32095403)
15. KNIGHT DM, WAGNER C, JORDAN R et al.: The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions. Mol. Immunol. (1995) 32(16):1271-1281. (Pubitemid 26015106)
16. TCHENG JE, ELLIS SG, GEORGE BS et al.: Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation (1994) 90(4):1757-1764. (Pubitemid 24320922)
17. MASCELLI MA, LANCE ET, DAMARAJU L et al.: Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation (1998) 97(17):1680-1688. (Pubitemid 28211416)
18. DERY JP, BRADEN GA, LINCOFF AM et al.: Final results of the ReoPro readministration registry. Am. J. Cardiol. (2004) 93(8):979-984. (Pubitemid 38479450)
19. TCHENG JE, KEREIAKES DJ, LINCOFF AM et al.: Abciximab readministration: results of the ReoPro Readministration Registry. Circulation (2001) 104(8):870-875. (Pubitemid 32778035)
20. BOERSMA E, AKKERHUIS KM, THEROUX P et al.: Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation (1999) 100(20):2045-2048. (Pubitemid 29532053)
21. SIMOONS ML: Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet (2001) 357(9272):1915-1924. (Pubitemid 32568331)
22. HARRINGTON RA, BECKER RC, EZEKOWITZ M et al.: Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 126(3 Suppl.):513S-548S. (Pubitemid 39302604)
23. NO AUTHORS LISTED: Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N. Engl. J. Med. (1998) 338(21):1488-1497.
24. HAMM CW, HEESCHEN C, GOLDMANN B et al.: Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N. Engl. J. Med. (1999)
25. 340(21):1623-1629. 25. NO AUTHORS LISTED: Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N. Engl. J. Med. (1998) 339(7):436-443.
26. ANTMAN EM, COHEN M, BERNINK PJ et al.: The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA (2000) 284(7):835-842. (Pubitemid 30643610)
27. BARTHOLOMEW BA, SHEPS DS, MONROE S et al.: A population-based evaluation of the thrombolysis in myocardial infarction risk score for unstable angina and non-ST elevation myocardial infarction. Clin. Cardiol. (2004) 27(2):74-78. (Pubitemid 38155697)
28. MORROW DA, ANTMAN EM, SNAPINN SM et al.: An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS. Eur. Heart J. (2002) 23(3):223-229. (Pubitemid 36358244)
29. TOPOL EJ, MOLITERNO DJ, HERRMANN HC et al.: Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N. Engl. J. Med. (2001) 344(25):1888-1894. (Pubitemid 32553357)
30. NEUMANN FJ, KASTRATI A, POGATSA-MURRAY G et al.: Evaluation of prolonged antithrombotic pretreatment ('cooling-off' strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial. JAMA (2003) 290(12):1593-1599. (Pubitemid 37441261)
31. CANNON CP, WEINTRAUB WS, DEMOPOULOS LA et al.: Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N. Engl. J. Med. (2001) 344(25):1879-1887. (Pubitemid 32564900)
32. KLEIMAN NS, OHMAN EM, CALIFF RM et al.: Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. J. Am. Coll. Cardiol. (1993) 22(2):381-389. (Pubitemid 23214549)
33. OHMAN EM, KLEIMAN NS, GACIOCH G et al.: Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. Circulation (1997) 95(4):846-854. (Pubitemid 27091524)
34. NO AUTHORS LISTED: Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial. J. Am. Coll. Cardiol. (1998) 32(7):2003-2010. (Pubitemid 29010468)
35. ANTMAN EM, GIUGLIANO RP, GIBSON CM et al.: Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation (1999) 99(21):2720-2732. (Pubitemid 29250016)
36. NO AUTHORS LISTED: Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Circulation (2000) 101(24):2788-2794.
37. TOPOL EJ: Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet (2001) 357(9272):1905-1914. (Pubitemid 32568330)
38. LINCOFF AM, CALIFF RM, VAN DE WERF F et al.: Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy versus conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. JAMA (2002) 288(17):2130-2135. (Pubitemid 35265380)
39. ASSESSMENT OF THE SAFETY AND EFFICACY OF A NEW THROMBOLYTIC REGIMEN (ASSENT)-3 INVESTIGATORS: Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet (2001) 358(9282):605-613. (Pubitemid 32786824)
40. DE LUCA G, SURYAPRANATA H, STONE GW et al.: Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA (2005) 293(14):1759-1765. (Pubitemid 40491302)
41. STONE GW, GRINES CL, COX DA et al.: Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N. Engl. J. Med. (2002) 346(13):957-966. (Pubitemid 34983245)
42. TCHENG JE, KANDZARI DE, GRINES CL et al.: Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation (2003) 108(11):1316-1323. (Pubitemid 37174408)
43. MONTALESCOT G, BARRAGAN P, WITTENBERG O et al.: Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N. Engl. J. Med. (2001) 344(25):1895-1903. (Pubitemid 32553358)
44. ADMIRAL INVESTIGATORS: Three-year duration of benefit from abciximab in patients receiving stents for acute myocardial infarction in the randomized double-blind ADMIRAL study. Eur. Heart J. (2005) 26(23):2520-2523. (Pubitemid 41677301)
45. NEUMANN FJ, KASTRATI A, SCHMITT C et al.: Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J. Am. Coll. Cardiol. (2000) 35(4):915-921. (Pubitemid 30189922)
46. ANTONIUCCI D, RODRIGUEZ A, HEMPEL A et al.: A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J. Am. Coll. Cardiol. (2003) 42(11):1879-1885. (Pubitemid 37485558)
47. MONTALESCOT G, BORENTAIN M, PAYOT L, COLLET JP, THOMAS D: Early versus late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. JAMA (2004) 292(3):362-366. (Pubitemid 38944261)
48. GODICKE J, FLATHER M, NOC M et al.: Early versus periprocedural administration of abciximab for primary angioplasty: a pooled analysis of 6 studies. Am. Heart J. (2005) 150(5):1015. (Pubitemid 41607790)
49. KONG DF, HASSELBLAD V, HARRINGTON RA et al.: Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions. Am. J. Cardiol. (2003) 92(6):651-655. (Pubitemid 37103012)
50. NORDMANN AJ, HENGSTLER P, LEIMENSTOLL BM et al.: Clinical outcomes of stents versus balloon angioplasty in non-acute coronary artery disease. A meta-analysis of randomized controlled trials. Eur. Heart J. (2004) 25(1):69-80. (Pubitemid 38055595)
51. KASTRATI A, MEHILLI J, SCHUHLEN H et al.: A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N. Engl. J. Med. (2004) 350(3):232-238. (Pubitemid 38071801)
52. KASTRATI A, MEHILLI J, NEUMANN FJ et al.: Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA (2006) 295(13):1531-1538.
53. BHATT DL, MARSO SP, LINCOFF AM et al.: Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J. Am. Coll. Cardiol. (2000) 35(4):922-928. (Pubitemid 30189923)
54. MEHILLI J, KASTRATI A, SCHUHLEN H et al.: Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation (2004) 110(24):3627-3635. (Pubitemid 40003783)
55. MATHEW V, GRILL DE, SCOTT CG et al.: The influence of abciximab use on clinical outcome after aortocoronary vein graft interventions. J. Am. Coll. Cardiol. (1999) 34(4):1163-1169. (Pubitemid 29500555)
56. MUHLESTEIN JB, KARAGOUNIS LA, TREEHAN S, ANDERSON JL: 'Rescue' utilization of abciximab for the dissolution of coronary thrombus developing as a complication of coronary angioplasty. J. Am. Coll. Cardiol. (1997) 30(7):1729-1734. (Pubitemid 27521256)
57. ABCIXIMAB EMERGENT STROKE TREATMENT TRIAL (AbESTT) INVESTIGATORS: Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized Phase II trial. Stroke (2005) 36(4):880-890. (Pubitemid 40490643)
58. HOFMANN R, KERSCHNER K, STEINWENDER C et al.: Abciximab bolus injection does not reduce cerebral ischemic complications of elective carotid artery stenting: a randomized study. Stroke (2002) 33(3):725-727. (Pubitemid 34203998)
59. RAJAN DK, PATEL NH, VALJI K et al.: Quality improvement guidelines for percutaneous management of acute limb ischemia. J. Vasc. Interv. Radiol. (2005) 16(5):585-595. (Pubitemid 40647203)
60. SCHAFER AI: Antiplatelet therapy. Am. J. Med. (1996) 101(2):199-209. (Pubitemid 26296782)
61. NO AUTHORS LISTED: Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet (1997) 349(9063):1429-1435. (Pubitemid 27212191)
62. http://www.gene.ucl.ac.uk/nomenclature/aboutHGNC.html HUGO Gene Nomenclature Committee website 2006.
63. http://www.clinicaltrial.gov/ct/show/NCT00046228 US NIH clinical trials website; FINESSE trial.
64. http://www.centocor.com/news/news-103105.jsp Centocor website, Patient Enrollment Permanently Discontinued in Investigational Clinical Trial of REOPRO® (abciximab) for Acute Ischemic Stroke.